Journal
BLOOD ADVANCES
Volume 5, Issue 6, Pages 1638-1647Publisher
ELSEVIER
DOI: 10.1182/bloodadvances.2020003645
Keywords
-
Categories
Funding
- Swedish Cancer Society CAN [2012/774, 19 0109 SCIA]
- Karolinska Institutet [5-63/2015]
- Janssen Pharmaceuticals NV [5-63/2015]
- Swedish Cancer Society [19 0123 Pj 01 H]
- Swedish Society of Medicine
- United Kingdom's Medical Research Council Methodology Research Panel [MR/P015433/1]
Ask authors/readers for more resources
The study found that some mantle cell lymphoma patients do not undergo autologous hematopoietic cell transplantation (AHCT) following initial diagnosis, with unmarried/divorced patients, those with lower education levels, and comorbid patients more likely to choose not to undergo AHCT. Receiving AHCT was associated with a reduced all-cause mortality rate, while patients not receiving AHCT had a higher mortality rate.
It is unknown how many mantle cell lymphoma (MCL) patients undergo consolidation with autologous hematopoietic cell transplantation (AHCT), and the reasons governing the decision, are also unknown. The prognostic impact of omitting AHCT is also understudied. We identified all MCL patients diagnosed from 2000 to 2014, aged 18 to 65 years, in the Swedish Lymphoma Register. Odds ratios (ORs) and 95% confidence intervals (CIs) from logistic regression models were used to compare the likelihood of AHCT within 18 months of diagnosis. All-cause mortality was compared between patients treated with/without AHCT using hazard ratios (HRs) and 95% CIs estimated from Cox regression models. Probabilities of being in each of the following states: alive without AHCT, alive with AHCT, dead before AHCT, and dead after AHCT, were estimated over time from an illness-death model. Among 369 patients, 148 (40%) were not treated with AHCT within 18 months. Compared with married patients, never married and divorced patients had lower likelihood of undergoing AHCT, as had patients with lower educational level, and comorbid patients. Receiving AHCT was associated with reduced all-cause mortality (HR = 0.58, 95% CI: 0.40-0.85). Transplantation-related mortality was low (2%). MCL patients not receiving an AHCT had an increased mortality rate, and furthermore, an undue concern about performing an AHCT in certain societal groups was seen. Improvements in supportive functions potentially increasing the likelihood of tolerating an AHCT and introduction of more tolerable treatments for these groups are needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available